

iv) providing a Hp-Hb complex, or a part thereof, or a mimic thereof as defined in claim 1 capable of binding to the CD163 variant,

v) operably linking a substance as defined in claim 1 to the Hp-Hb complex, or a part thereof, or a mimic thereof,

vi) administering the substance operably linked to the Hp-Hb complex, or a part thereof, or a mimic thereof to an individual in need thereof,

wherein the method comprises drug-delivery treatment of an individual in need of such treatment.

30. (Amended) A method of treatment of an individual comprising administration of the Hp-Hb complex, or a part thereof, or a mimic thereof according to claim 1, the method comprising the steps of:

iv) providing a Hp-Hb complex, or a part thereof, or a mimic thereof as defined in claim 1 capable of binding to the CD163 variant,

v) operably linking a substance as defined in claim 1 to the Hp-Hb complex, or a part thereof, or a mimic thereof,

vi) administering the substance operably linked to the Hp-Hb complex, or a part thereof, or a mimic thereof to an individual in need thereof,

wherein the method comprises gene delivery treatment of an individual in need of such treatment.

31. (Amended) A method of treatment of an individual comprising administration of the Hp-Hb complex, or a part thereof, or a mimic thereof according to claim 1, the method comprising the steps of:

- iv) providing a Hp-Hb complex, or a part thereof, or a mimic thereof as defined in claim 1 capable of binding to the CD163 variant,
- v) operably linking a substance as defined in claim 1 to the Hp-Hb complex, or a part thereof, or a mimic thereof,
- vi) administering the substance operably linked to the Hp-Hb complex, or a part thereof, or a mimic thereof to an individual in need thereof,

wherein the method comprises treatment of haemolysis in an individual in need of such treatment.

Please add new claim:

38. A method of treatment of haemolysis in an individual comprising administration of a CD163 variant according to claim 19.

REMARKS

The above amendments to the claims are being made in order to eliminate multiple dependency and for the purpose of reducing the filing fee. Please enter this amendment prior to calculation of the filing fee in this case.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current